Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
Published: 03 December 2019
-
Views:
37
-
Likes:
7
-
Views:
37
-
Likes:
7
Overview
The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.
Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
Learning Objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
- Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
- Assess the interrelationships linking diabetes, HF and CVD
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
More from this programme
Part 1
SGLT2 in HF Now and the Future
| 1 session | |
| SGLT2 in HF Now and the Future | Watch now |
Part 2
DAPA-HF Trial Design Rationale
| 1 session | |
| DAPA-HF Trial Design Rationale | Watch now |
Part 3
SGLT2 beyond diabetes
| 1 session | |
| SGLT2 beyond diabetes | Watch now |
Part 4
Guidelines, Recent Data & Future Practices
Part 5
DAPA-HF Trial
| 1 session | |
| DAPA-HF Trial | Watch now |
Part 6
Discussion with the DAPA-HF Trialist
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational…
Carolyn Lam
Professor and Senior Consultant
Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.